 Strimvelis was approved  by the European Commission on 27 May 2016.As of 2016, the only site approved to manufacture the treatment was MolMed.In 2017, GSK announced it was looking to sell off Strimvelis, and in March 2018, GSK sold Strimvelis to Orchard Therapeutics Ltd.; as of that time there had been only five sales of the product.